{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:59:04Z","timestamp":1785484744779,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcyt.2026.102821","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:58:26Z","timestamp":1775260706000},"page":"102821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality control of biological raw materials to ensure the viral safety of cell and gene therapy products"],"prefix":"10.1016","volume":"28","author":[{"given":"Yusuke","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6684-1883","authenticated-orcid":false,"given":"Satomi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0837-5942","authenticated-orcid":false,"given":"Ayana","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyo","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-7029","authenticated-orcid":false,"given":"Yoshiaki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102821_bib0001","unstructured":"Standards for Biological Raw Materials, MHLW Notification No. 210, 2003. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000268474.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0002","unstructured":"Standards for Biological Raw Materials, Operational Guideline, PFSB\/ELD Notification No. 1002-1, PFSB\/MDRMPE Notification No. 1002-5, 2014. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000268475.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0003","unstructured":"Questions and Answers (Q&A) on the Operation of the Standards for Biological Raw Materials, PFSB\/ELD, PFSB\/MDRMPE Administrative Notice, 2015. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000275496.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0004","unstructured":"Ensuring the Quality and Safety of Drugs, etc. Manufactured from Raw Materials of Human or Animal Origin, PMSB Notification No. 1314, 2000. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000275003.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0005","unstructured":"Guideline on ensuring quality and safety of products derived from processed cell and tissue (Autologous cells), PFSB Notification No. 0208003, 2008. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000278367.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0006","unstructured":"Guideline on ensuring quality and safety of products derived from processed cell and tissue (Allogeneic cells), PFSB Notification No. 0912006, 2008. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000278366.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0007","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.reth.2015.05.002","article-title":"A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human somatic stem cells","volume":"2","author":"Hayakawa","year":"2015","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.reth.2015.05.001","article-title":"A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human somatic stem cells","volume":"2","author":"Hayakawa","year":"2015","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.reth.2015.06.002","article-title":"A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells","volume":"2","author":"Hayakawa","year":"2015","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.reth.2015.06.004","article-title":"A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-like) cells","volume":"2","author":"Hayakawa","year":"2015","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0011","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.reth.2015.06.001","article-title":"A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human embryonic stem cells","volume":"2","author":"Hayakawa","year":"2015","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0012","unstructured":"WHO technical report series 1004; WHO expert committee on biological standardization. Sixty-seventh report; 2017. [accessed 12.03.26]. Available from:https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/d4fbe58a-ef0c-4bc2-812b-ab4952e89f13\/content"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102821_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1537-2995.2004.04215.x","article-title":"A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors","volume":"45","author":"Busch","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2026.102821_bib0014","doi-asserted-by":"crossref","unstructured":"Stramer SL, Dodd RY Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress. Transfusion. 2013;53(10pt2): 2375-83. Available from: https:\/\/doi.org\/10.1111\/trf.12371","DOI":"10.1111\/trf.12371"},{"key":"10.1016\/j.jcyt.2026.102821_bib0015","unstructured":"Derivation and characterisation of cell substrates used for production of biotechnological\/biological products (Q5D). [accessed 12.03.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000156854.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0016","unstructured":"Good Manufacturing Practice guide for active pharmaceutical ingredients (Q7). [accessed 12.03.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000156709.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0017","unstructured":"Japanese Pharmacopoeia 18th Edition. Basic requirements for viral safety of biotechnological\/biological products listed in Japanese Pharmacopoeia <G3-13-141>. [accessed 12.02.26]. Available from: https:\/\/www.mhlw.go.jp\/content\/11120000\/000904454.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0018","unstructured":"Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (Q5A(R2)). [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000265997.pdf"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102821_bib0019","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/bit.28017","article-title":"Virus filtration: a review of current and future practices in bioprocessing","volume":"119","author":"Johnson","year":"2022","journal-title":"Biotechnol Bioeng"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102821_bib0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/bit.22662","article-title":"Analysis of viral clearance unit operations for monoclonal antibodies","volume":"106","author":"Miesegaes","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.jcyt.2026.102821_bib0021","unstructured":"Ancillary Materials for Regenerative Medical Products. FIRM List of products with certification of suitability for ancillary material. [accessed 12.02.26]. Available from: https:\/\/firm.or.jp\/en\/AMList\/"},{"key":"10.1016\/j.jcyt.2026.102821_bib0022","unstructured":"Master File System. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/mf\/0001.html"},{"key":"10.1016\/j.jcyt.2026.102821_bib0023","unstructured":"Publication of the API Master File (MF) [in Japanese]. [accessed 12.02.26]. Available from: https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/master-files\/0008.html"},{"key":"10.1016\/j.jcyt.2026.102821_bib0024","first-page":"681","article-title":"Virus stalls Genzyme plant","volume":"27","author":"Bethencourt","year":"2009","journal-title":"Nature Biothecnology"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102821_bib0025","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02690-09","article-title":"Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus","volume":"84","author":"Victoria","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2026.102821_bib0026","unstructured":"Advancing the Development of the Biopharmaceutical Industry, Planning Subcommittee, Bioeconomy Committee, Japan Business Federation November 7, 2023 [in Japanese]. [accessed 12.02.26]. Available from: https:\/\/www.keidanren.or.jp\/policy\/2023\/073_honbun.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0027","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reth.2020.10.004","article-title":"Gaps between Asian regulations for eligibility of human mesenchymal stromal cells as starting materials of cell therapy products and comparability of mesenchymal stromal cell-based products subject to changes in their manufacturing process","volume":"15","author":"Tanaka","year":"2020","journal-title":"Regen Ther"},{"key":"10.1016\/j.jcyt.2026.102821_bib0028","unstructured":"21 CFR 1271.80: What are the general requirements for donor testing? [accessed 12.02.26]. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-L\/part-1271\/subpart-C\/section-1271.80"},{"key":"10.1016\/j.jcyt.2026.102821_bib0029","unstructured":"Commission Directive 2006\/17\/EC of 8 February 2006 implementing Directive 2004\/23\/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. [accessed 12.02.26]. Available from: https:\/\/eur-lex.europa.eu\/eli\/dir\/2006\/17\/oj"},{"key":"10.1016\/j.jcyt.2026.102821_bib0030","unstructured":"Guide to the quality and safety of tissues and cells for human application, EDQM 5th Edition, 2022. [accessed 12.02.26]. Available from: https:\/\/www.edqm.eu\/en\/guide-to-the-quality-and-safety-of-tissues-and-cells-for-human-application1"},{"key":"10.1016\/j.jcyt.2026.102821_bib0031","unstructured":"FDA Draft Guidance for Industry. Recommendations for determining eligibility of donors of human cells, tissues, and cellular and tissue-based products (HCT\/Ps). 2025. [accessed 12.02.26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-determining-eligibility-donors-human-cells-tissues-and-cellular-and-tissue-based"},{"key":"10.1016\/j.jcyt.2026.102821_bib0032","unstructured":"FDA Draft Guidance for Industry. Recommendations to reduce the risk of transmission of hepatitis B virus (HBV) by human cells, tissues, and cellular and tissue-based products (HCT\/Ps). 2025. [accessed 12.02.26]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-hepatitis-b-virus-hbv-human-cells-tissues-and-cellular-and"},{"key":"10.1016\/j.jcyt.2026.102821_bib0033","unstructured":"FDA Draft Guidance for Industry. Recommendations to reduce the risk of transmission of hepatitis C virus (HCV) by human cells, tissues, and cellular and tissue-based products (HCT\/Ps). 2025. [accessed 12.02.26]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-hepatitis-c-virus-hcv-human-cells-tissues-and-cellular-and"},{"key":"10.1016\/j.jcyt.2026.102821_bib0034","unstructured":"FDA Draft Guidance for Industry. Recommendations to reduce the risk of transmission of human immunodeficiency virus (HIV) by human cells, tissues, and cellular and tissue-based products (HCT\/Ps). 2025. [accessed 12.02.26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-risk-transmission-human-immunodeficiency-virus-hiv-human-cells-tissues-and"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102821_bib0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcyt.2022.09.005","article-title":"Comparison of guidelines for biological ancillary materials used for the manufacture of gene and cellular therapy products in Asia","volume":"25","author":"Tanaka","year":"2023","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102821_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2015.09.010","article-title":"Current perspectives on the use of ancillary materials for the manufacture of cellular therapies","volume":"18","author":"Solomon","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102821_bib0037","unstructured":"United States Pharmacopoeia. 1024: Bovine serum. [accessed 12.02.26]. Available from: https:\/\/doi.usp.org\/USPNF\/USPNF_M2388_03_01.html"},{"key":"10.1016\/j.jcyt.2026.102821_bib0038","unstructured":"FDA Draft Guidance for Industry. Considerations for the use of human-and animal-derived materials in the manufacture of cell and gene therapy and tissue-engineered medical products. 2024. [accessed 12.02.26]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-human-and-animal-derived-materials-manufacture-cell-and-gene-therapy-and-tissue"},{"key":"10.1016\/j.jcyt.2026.102821_bib0039","unstructured":"European Pharmacopoeia. General Chapter 5.2.8.: Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. Strasbourg: European Directorate for the Quality of Medicines & HealthCare (EDQM); European Pharmacopoeia Commission."},{"key":"10.1016\/j.jcyt.2026.102821_bib0040","unstructured":"Guideline on the use of bovine serum in the manufacture of human biological medicinal products, EMA\/CHMP\/BWP\/457920\/2012 Rev 1, 2013. [accessed 12.02.26]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-bovine-serum-manufacture-human-biological-medicinal-products-revision-1_en.pdf"},{"issue":"94","key":"10.1016\/j.jcyt.2026.102821_bib0041","article-title":"Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples","volume":"5","author":"Lewandowska","year":"2017","journal-title":"Microbiome"},{"key":"10.1016\/j.jcyt.2026.102821_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2025.101859","article-title":"Report of the fourth conference on next-generation sequencing (NGS) for adventitious virus detection in biologics for humans and animals: validation and implementation of NGS","volume":"92","author":"Khan","year":"2025","journal-title":"Biologicals"},{"key":"10.1016\/j.jcyt.2026.102821_bib0043","unstructured":"Points to consider for replacement of conventional tests for viruses with next generation sequencing (NGS) assays (Early Consideration). [accessed 12.03.26]. Available from: https:\/\/www.pmda.go.jp\/files\/000278698.pdf"},{"key":"10.1016\/j.jcyt.2026.102821_bib0044","unstructured":"Project Completion Report, Study for the revision of \u201cthe Standards of Biological Raw Materials\u201d for development of emerging medicinal\/medical products, 2025 [in Japanese]. [accessed 12.02.26]. Available from: https:\/\/www.amed.go.jp\/content\/000149715.pdf"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:18:52Z","timestamp":1785482332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1465324926007826"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102821","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality control of biological raw materials to ensure the viral safety of cell and gene therapy products","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell and Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102821"}}